This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Industry-University Cooperation Foundation Hanyang University, Inje University Industry-Academic Cooperation Foundation. Active years: 2020-2022.
Company Filing History:
2 out of 1,232 
2 out of 69 Years Active: 2020-2022
Title: Sae-Gwang Park: Innovator in Vascular Biology
Introduction
Sae-Gwang Park is a prominent inventor based in Busan, South Korea. He has made significant contributions to the field of vascular biology, particularly through his innovative patents. With a total of 2 patents, Park's work focuses on advancing medical science and improving therapeutic strategies.
Latest Patents
One of his latest patents is titled "Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides." This invention discloses a fusion polypeptide designed to inhibit neovascularization. It includes a peptide that specifically binds to vascular endothelial growth factor (VEGF) receptors, along with a hydrophilic elastin-based polypeptide linked to the peptide. This innovative approach has the potential to significantly impact treatments related to vascular diseases.
Career Highlights
Throughout his career, Sae-Gwang Park has been associated with various esteemed institutions. He has worked with the Industry-University Cooperation Foundation at Hanyang University and the Inje University Industry-Academic Cooperation Foundation. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Dong Woo Lim and Min Jung Kang. Their collaborative efforts have further enhanced the research and development of innovative solutions in vascular biology.
Conclusion
Sae-Gwang Park's contributions to the field of vascular biology through his patents and collaborations highlight his role as a significant innovator. His work continues to pave the way for advancements in medical treatments and therapies.